Carthera, a Lyon and Paris, France-based developer of an ultrasound-based medical device, raised €37.5M in Series B funding.
The round was led by an undisclosed investor, alongside the European Innovation Council Fund (EICF), Panakès Partners, Relyens Innovation Santé (Turenne Santé) and Supernova Invest with its Supernova 2 fund.
The company intends to use the funds to launch a pivotal multicenter trial with its SonoCloud technology and to continue developing its clinical pipeline and technology.
Founded and led by CEO Frédéric Sottilini, Carthera is a clinical-stage medtech company focused on developing ultrasound-based medical devices to treat a wide range of brain disorders. SonoCloud is an intracranial implant that temporarily opens the Blood-Brain Barrier (BBB) and increases the concentration of therapeutic molecules in the brain. This ultrasound-induced opening of the blood-brain barrier offers a new treatment option for a wide range of indications, including brain tumors and Alzheimer’s disease. It is currently in clinical trials in Europe and the United States.
Carthera is a spin-off from AP-HP Paris and Sorbonne University that leverages the inventions of Pr. Alexandre Carpentier, head neurosurgeon at AP-HP Sorbonne university, who has achieved a recognition for his developments in treating brain disorders.
FinSMEs
27/06/2023